Persistent URL of this record https://hdl.handle.net/1887/97719
In Collections
This item can be found in the following collections:
RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PROGRESSING DESPITE PRIOR TREATMENT WITH AT LEAST IMATINIB (IM) AND SUNITINIB (SU) : GRID TRIAL
- All authors
- Nishida, T.; Casali, P.G.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.G.; Rutkowski, P.; Hohenberger, P.; Gelderblom, H.; Leahy, M.G.; Mehren, M. von; Schoffski, P.; Blackstein, M.E.; Cesne, A.L.; Badalamenti, G.; Xu, J.M.; Laurent, D.; Kuss, I.; Demetri, G.D.; GRID Investigators
- Date
- 2012-10-31
- Journal
- Annals of Oncology
- Volume
- 23
- Pages
- 20 - 20